Skip to main content
Alliance Equity Research
AER Insights
All insights
Market Commentary

More Shopping Trips Lift Target’s Earnings as Tariff Refunds Raise Its Outlook

Target’s third-quarter comparable sales rose 5.6%, driven mainly by more transactions. Gross margin improved even after removing $301 million of tariff refunds, although higher store labor and other costs absorbed some of the gain. The retailer raised its full-year earnings outlook, but most of the increase in the midpoint reflects refunds already recognized. The distinction matters as Target prepares to spend $5 billion to $6 billion on capital projects in 2027. Holiday traffic, markdowns and cash tied up in merchandise will help show how much of the improvement can carry forward.

Updated 6 min read
An empty shopping cart in a retail aisle stocked with holiday home goods.

Target earned $1.37 billion in third-quarter operating profit after excluding $301 million in tariff refunds, about 24% above last year’s adjusted result. Comparable transactions rose 5.0%, while average spending per transaction increased just 0.6%. Gross margin also improved independently of the refund, helped by lower markdown pressure than a year earlier and productivity gains in the supply chain.

Shoppers made more trips

Target sells groceries, household essentials and discretionary goods such as clothing, toys and home furnishings through more than 2,000 U.S. stores and online. Its stores also fulfill online orders through services including pickup and delivery. A customer who orders online for pickup is counted in digital sales even though a store handles the order. In the third quarter, 19.8% of merchandise sales originated digitally, while stores fulfilled 97.4% of merchandise sales across all channels.

Net sales rose from $25.27 billion to $27.07 billion in the quarter ended October 31. Merchandise accounted for $1.70 billion of the $1.80 billion increase. Comparable sales, which track merchandise sales excluding stores open less than 13 months or closed stores, rose 4.6% in stores and 9.8% digitally. Across the comparable base, average spending per transaction increased only 0.6%. The quarter therefore depended much more on the number of purchases than on customers spending more each time.

Target reported sales growth across most of its main merchandise categories and said back-to-school and college shopping produced the strongest sales growth of the quarter. This year’s gain followed a 2.7% decline in comparable sales a year earlier. Comparable sales were about 2.7% above their level two years earlier.

Sales of toys and other hardlines, which Target groups under Fun 101, rose 27%, or $856 million. That was about half the increase in merchandise sales. Food and beauty together added $691 million, while apparel and accessories sales fell $147 million. The mix gives Target a stronger sales base heading into the holidays, although the gains were uneven across discretionary categories.

Gross margin recovered alongside tariff refunds

Target recorded $301 million of tariff refunds as a reduction in cost of sales. That treatment lifted gross margin and operating profit by the same dollar amount. After removing the refund, gross margin was about 29.4% versus 28.2% a year earlier. Target attributed the underlying improvement to a comparison with heavier markdowns and higher tariffs last year, productivity gains at supply chain facilities, and growth in non-merchandise sales. Higher freight and fuel costs, investments in value and an unfavorable mix of merchandise partly offset those benefits.

Fiscal third quarter20252026
Net sales$25,270m$27,067m
Reported gross profit$7,133m$8,259m
Reported operating income$948m$1,672m
Adjusted operating income$1,109m$1,672m
GAAP diluted EPS$1.51$2.65
Adjusted diluted EPS$1.78$2.65
Source: Target’s Q3 financial statements and non-GAAP reconciliation. Target made no adjustment to 2026 operating income, so both figures include the $301 million refund. The 2025 adjustment added back $161 million of business transformation costs.

Excluding refunds, operating income was $1.37 billion, approximately 24% above last year’s adjusted $1.11 billion. On this basis operating margin rose from about 4.4% to 5.1%. The improvement was smaller than the gross margin gain because selling and administrative costs rose to 21.9% of sales from 21.3% on last year’s adjusted basis. Target cited higher incentive pay, more store labor hours and planned spending on stores. Greater sales helped absorb those costs, but did not fully offset their effect on the expense ratio.

Advertising, card profit sharing and other non-merchandise sales totaled $618 million, up from $518 million. They accounted for about 2.3% of total sales. That makes them relevant to gross margin, as management noted, while merchandise volume remains the primary driver of revenue growth. Target also classifies some of its Roundel advertising arrangements as offsets to costs, so reported advertising revenue does not capture the full contribution of that business.

Quarterly net earnings rose from $689 million to $1.21 billion. Lower net interest expense helped, while a higher tax rate partly offset the increase in pretax profit. Reported and adjusted diluted EPS both reached $2.65. Removing the disclosed $0.50 refund benefit gives about $2.15, up roughly 21% from last year’s $1.78 adjusted EPS. The prior-year adjustment excluded business transformation expenses.

Cash generation improved as payables rose

Operating cash flow for the first nine months increased to $5.73 billion from $3.49 billion, a gain of $2.24 billion. Target received about $1.3 billion in tariff refunds during the period. Net earnings rose $1.21 billion, and the noncash deferred tax adjustment added $338 million to the year-over-year cash flow comparison. Inventory absorbed $3.84 billion, up from $2.16 billion, while growth in accounts payable provided $2.80 billion, up from $658 million. Taken together, inventory and payables used $453 million less cash than a year earlier.

At October 31, inventory stood at $16.14 billion, up 8.4% from the prior-year quarter-end. Payables stood at $15.51 billion, up 12.5% on the same comparison. These are end-of-quarter balances, while the cash flow statement measures movements since the start of the fiscal year. The build in payables helped finance merchandise purchases ahead of the holidays. Target needs to convert that merchandise into sales as supplier bills come due.

Capital spending increased from $2.84 billion to $3.76 billion over the same nine months. Operating cash flow less capital spending was about $1.97 billion versus $643 million. That measure precedes dividends and debt repayments. Target paid $1.56 billion of dividends and reduced long-term debt by $1.11 billion during the period. Cash and equivalents stood at $4.46 billion on October 31, down from $5.49 billion at the start of the fiscal year.

What the higher outlook implies

Target raised its 2026 sales growth outlook from around 5% to around 6%. The midpoint of its full-year EPS range rose by about $0.63 as the range moved from $9.90–$10.90 to $10.65–$11.40. After subtracting the disclosed refunds of about $1.65 per share in the August outlook and $2.14 in November, the midpoint rose from $8.75 to about $8.89. The full-year operating margin outlook excluding refunds stayed around 5.1%. Subtracting nine-month diluted EPS of $8.47 from the latest full-year range implies roughly $2.18 to $2.93 for the fourth quarter. The estimate is approximate because quarterly and full-year share counts can differ.

Target expects $5 billion to $6 billion of capital spending in 2027, compared with about $5 billion in 2026. The holiday quarter will show how readily Target can turn its larger inventory into cash. If transactions keep rising and Target sells through inventory without deeper markdowns, it can replenish cash as supplier bills come due while retaining more gross profit on those sales.

This material is provided for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.

Companies Discussed

About AER Insights

Alliance Equity Research publishes timely insights on company-specific developments, industry trends, capital markets activity, and emerging investment themes across global public markets, with a particular focus on undercovered companies, sectors, and developments that often receive limited attention from mainstream financial research. Our analysis focuses on the financial, strategic, and valuation implications behind the headlines, using company disclosures, filings, market data, and sector context to help investors understand what matters, why it matters, and what to watch next.

Get AER Insights by Email

Receive new AER Insights and research updates in your inbox.

Subscribe
Unlabeled vaccine vial in a laboratory with an illustrative blood-cell background.Biotechnology & Healthcare

SELLAS Reports a Survival Benefit in AML as Its Cancer Vaccine Approaches FDA Review

SELLAS Life Sciences reported that its investigational cancer vaccine met the overall-survival endpoint in a Phase 3 trial of patients with acute myeloid leukemia who had reached a second or later remission and could not undergo a donor stem cell transplant. Median survival was 24.0 months with galinpepimut-S versus 14.7 months with investigator-selected care. The result provides a basis for a planned FDA discussion, while detailed control-arm, safety and secondary-endpoint data remain important to interpretation. SELLAS ended September with $134.7 million in cash after substantial warrant exercises.

Gaurav Premani, CFANovember 17, 20267 min read
Read article
Glass capsule on a laboratory surface against an abstract neural network.Biotechnology & Healthcare

Helus Pharma’s Depression Trial Succeeds as Safety and Funding Questions Move Forward

Helus Pharma’s HLP003 met the primary endpoint in its first pivotal depression trial, producing a 7.6-point advantage over placebo on a symptom scale at six weeks. Patients remained on their existing antidepressants, and the benefit persisted at the study’s 12-week assessment. The results strengthen the case for an intermittent add-on treatment, although the nature of three treatment-related serious adverse events remains undisclosed. Quarterly filings show $171.1 million in cash at September 30 and continued clinical spending ahead of a second pivotal readout expected in late 2027.

Gaurav Premani, CFANovember 16, 20268 min read
Read article
Conceptual image of an unbranded medicine vial and blood glucose meter.Biotechnology & Healthcare

Amylyx’s Detailed Avexitide Results Bring a Rare Post-Surgery Condition Closer to Treatment

Amylyx has released detailed Phase 3 results for avexitide, an experimental daily injection for recurrent low blood sugar after gastric bypass. In 78 adults receiving dietary management, the treatment reduced the rate of specified hypoglycemic events over 16 weeks versus placebo. The company plans to seek U.S. approval by year-end and prepare for a possible 2027 launch. The study provides a clearer picture of the potential benefit, while diagnosis, insurance access, the approved patient population and sustained treatment will determine the commercial opportunity.

Gaurav Premani, CFANovember 15, 20266 min read
Read article
Two excavators in a dusty landscape digging among oversized graphics cardsMarket Commentary

AI Gold Rush: Inside the Multi-Trillion-Dollar AI Arms Race With No Clear Payoff (Yet)

With tech giants pouring billions into chips, data centers, and power grids despite unclear returns. Is the payoff coming, or is this a high-stakes gamble?

Gaurav Premani, CFAAugust 6, 202517 min read
Read article
View all insights

About Alliance Equity Research

Alliance Equity Research publishes independent and company-sponsored equity research on undercovered, emerging, and high-potential public companies globally. Our analyst-built, model-backed research combines fundamental business analysis, financial forecasting, and valuation.

Email: info@alliancekp.com · Website: https://allianceequityresearch.com

For detailed company research, financial models, or coverage inquiries, contact our research team.

Research commentary for informational purposes. This document does not constitute personalized investment advice or a Buy, Hold, or Sell recommendation. For important disclosures, including information about research sponsorship and potential conflicts of interest, visit allianceequityresearch.com/disclosures.